Trials / Completed
CompletedNCT00664716
Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants
Assessment Of Safety, Efficacy, PK&PD Of BG9924 in RA Patients Who Have Had An Inadequate Response To Conventional DMARD Therapy.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 391 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Safety and efficacy of BG9924 in RA participants that have had an inadequate response to disease-modifying anti-rheumatic drug (DMARD) therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Baminercept alfa 1 | experimental - one dose level |
| BIOLOGICAL | Placebo | Placebo comparator |
| BIOLOGICAL | Baminercept alfa 2 | experimental - second dose level |
| BIOLOGICAL | Baminercept alfa 3 | experimental - third dose level |
| BIOLOGICAL | Baminercept alfa 4 | experimental - fourth dose level |
| BIOLOGICAL | Baminercept alfa 5 | experimental - fifth dose level |
Timeline
- Start date
- 2007-07-01
- Primary completion
- 2008-10-01
- Completion
- 2008-10-01
- First posted
- 2008-04-23
- Last updated
- 2016-01-21
Locations
8 sites across 8 countries: Argentina, Brazil, Hungary, Mexico, Poland, Romania, Russia, United Kingdom
Source: ClinicalTrials.gov record NCT00664716. Inclusion in this directory is not an endorsement.